In-line Filtration Reduces Postoperative Phlebitis.

A randomised, controlled, clinical trial is performed at the Department of Anesthesia and Intensive Care of the Azienda Ospedaliero-Universitaria Careggi in Florence, Italy, to assess the effects of in-line filtration on the incidence of postoperative phlebitis. The Ethical Committee of the institution has approved the study (CEAV IN17/0000015). Patients preoperatively sign consent forms for participation in this trial.

An incidence of phlebitis equal to 50% within 48 hrs from peripheral venous cannulation has been preliminarily described in our centre during standard care (unpublished data). Two hundred and sixty-eight patients undergoing surgery are 1:1 randomised to in-line filtration (study group) and standard care (control group) to observe a 20% reduction in postoperative phlebitis within 48 hrs after surgery in the study group through a one-side chi-square analysis with statistical power of 90% and statistical significance of 0.025.

Every surgical patient scheduled for surgery, who preoperatively signed the consent form and underwent peripheral venous cannulation, is considered for this study. Patients undergoing central venous catheterisation or long-/middle-term peripheral cannulation are excluded.

On the day of surgery, all enrolled patients undergo standard peripheral venous cannulation according to the up-to-date standard of care. After placement of venous cannula and before the induction of anaesthesia, patients are randomised for in-line filtration or standard care.

For patients randomized to in-line filtration, in-line filters (Pall, Dreieich, Germany) are used during anaesthesia and the following 96 postoperative hours.

Patients randomised to standard care (control group) are managed without an in-line filter and according to local routine practice for intravenous drug administration in the adult patient. The enrolment in this study don't influence the type of anaesthesia or the postoperative pharmacological treatment previously scheduled for the patient.

The incidence and severity of phlebitis are evaluated using the Visual Infusion Phlebitis (VIP) Score every 12 hrs from the end of surgery until 96 hrs postoperatively. The postoperative VIP score evaluations are performed by another author, blinded to each patient's randomisation group. This filter are held by containment bands on the patient's arm and are completely covered by a breathable dressing medication to maintain the evaluator blind on the patient's randomisation group. The dressing medication never covers the vein where the cannulae are placed. Transparent dressing is used for cannula medication to allow cannulation site inspection

Phlebitis is defined as a VIP score ≥2. The primary end-point of the study is to assess the incidence of phlebitis in the 48 postoperative hours using a Fisher's exact test. Time and severity of phlebitis and time and causes for venous cannula removal are all compared between groups. In particular, data distribution is assessed through the Shapiro-Wilk test. Continuous data are presented as a median and interquartile range (IQR) or mean ± standard deviation (SD) and analysed through a Mann-Whitney or Student's t-test, according to data distribution. Qualitative data are presented as percentages and analysed through chi-square analysis. The Bonferroni adjustment is used for multiple comparisons. The lifespan of the cannulae is described for the study and the control groups through the Kaplan-Meier curve. Multivariate Cox regression analysis with a backwards selection is performed to evaluate the effect of in-line filtration on the risk of phlebitis and cannula removal, independently from other factors. Results are presented as p-value, hazard ratio (HR) and 95% confident interval (95%CI)

Inclusion criteria

• Age>18 years old
• Consent to trial participation and randomization obtained in preoperative period

Exclusion criteria

• Pregnancy
• Presence of central vascular access with central or peripheral iserction
• Presence of long peripheral vascular access such as Midline or MiniMidline
• Patients envolved in other comparative trial